Compare Hut 8 Corp (HUT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Hut 8 CorpTrade

Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Hut 8 Corp vs Recursion Pharmaceuticals Inc — how do they compare? Hut 8 Corp trades at $107.22 (market cap $11.36B), while Recursion Pharmaceuticals Inc trades at $3.04 (market cap $1.53B). The key difference: Hut 8 Corp is far larger — about 7.4× Recursion Pharmaceuticals Inc's market cap, and Hut 8 Corp is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.

	HUT	RXRX
Market Cap	$11.36B	$1.53B
Sector	Technology	Health
52-Week High	$133.02	$6.79
52-Week Low	$19.45	$2.84
Enterprise Value	$11.63B	$946.50M

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hut 8 Corp

HUT trades at $100.93, up 10.37% in the past 24 hours, with a bearish technical signal from moving averages and oscillators. The company reported a net loss of $226.15 million in 2025 despite revenue of $235.12 million, though it beat EPS estimates in two of the last three quarters. Recent news highlights its pivot to AI infrastructure, including a $4.25 billion bond issuance for data center projects (PRNewsWire, 2026-06-09).

Analyst consensus is strongly bullish with a $138.89 price target, but high valuation ratios and persistent losses pose risks. The stock's outlook hinges on successful execution of its digital infrastructure strategy, though cash flow challenges and competitive pressures remain key concerns for investors.

Recursion Pharmaceuticals Inc

RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.

The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

HUT

Hut 8 Mining signs $9.8B lease, AMC beats Q2 estimates, Replenish Nutrients secures $15M investmentProactive Investors · 22 hours agoBullish Hut 8 signs $9.8B lease to expand AI data center capacity, Needham raises price target to $145Tony Dante · 1 day agoBullish Hut 8 doubles AI data center lease capacity to 704 MW with $9.8B 15-year contract at Beacon Point campusPRNewsWire · 1 day agoBullish View details →

RXRX

View details →

About Hut 8 Corp

Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.